Want to see HK:2552 full AI Analyst Report?
2552 Stock Chart & Stats
HK$2.36
-HK$0.02(-0.79%)
At close: 4:00 PM EDT
HK$2.36
-HK$0.02(-0.79%)
Day’s Range― - ―
52-Week RangeHK$1.97 - HK$4.95
Previous CloseN/A
Volume865.87K
Average Volume (3M)1.70M
Market Cap
HK$2.45B
Enterprise ValueHK$1.29K
Total Cash (Recent Filing)HK$1.09B
Total Debt (Recent Filing)HK$301.80M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume1,266,927
30 Day Avg. Volume1,703,175
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)HK$1.06B
Bulls Say, Bears Say
Bulls Say
First-in-class Diabetes ProductDorzagliatin’s first-in-class status and active commercialization give Hua Medicine an established product platform in China’s diabetes market. A marketed therapy can support prescription adoption, indication expansion, and future pipeline partnering as the company builds scale.
Revenue And Gross-margin ImprovementAccelerating revenue growth alongside a materially higher gross margin indicates improving product economics and commercial traction. If sustained, this combination can increase contribution from each sale and provide a stronger foundation for eventual operating leverage.
Improved Balance-sheet PositionManageable leverage and restored positive equity improve financial resilience relative to 2024. Stable total debt limits balance-sheet deterioration and gives the company more flexibility to support commercialization and development while it works toward profitability.
Bears Say
Persistent Operating LossesThe core business remains substantially loss-making despite stronger revenue and gross margin, showing that scale has not yet produced sustainable operating leverage. Continued losses can consume resources and delay internally funded investment in dorzagliatin and the pipeline.
Negative Cash GenerationNegative operating and free cash flow indicate that reported growth is not currently converting into internally generated funding. Persistent cash burn would increase reliance on balance-sheet flexibility or external financing and could constrain investment in products and development.
Volatile And Lower-quality EarningsThe sharp gap between positive net income and negative operating performance suggests that earnings may depend on non-operating items rather than repeatable commercial profitability. Equity volatility further reduces confidence in the stability and durability of reported returns.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$1.97 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$2.45B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 189 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Aug 20, 2026. The company reported -HK$0.035 earnings per share for the quarter.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -HK$0.035 in its last earnings report. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
2552 Company Deck
2552 Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―